Fundz
Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Hot Spot Therapeutics Appoints Alison O'neill, M.D. As Chief Medical Officer

PRIVATESep 19, 2024•over 1 year ago

Position

Chief Medical Officer

Company

Hot Spot Therapeutics

Alison O'Neill, M.D.
Boston

Description

HotSpot Therapeutics, Inc. announced the appointment of Alison O'Neill, M.D., an accomplished industry leader, as Chief Medical Officer. Her extensive biopharmaceutical experience and proven track record in clinical development strategy and execution will be invaluable as the company advances its pipeline of innovative allosteric drug candidates.

Company Information

Company

Hot Spot Therapeutics

Location

Boston, Massachusetts, United States

About

HotSpot Therapeutics is targeting naturally occurring pockets on proteins called "natural hotspots" that are decisive in the control of cellular protein function. Largely unexploited by industry, these pockets are highly attractive for drug discovery and enable the systematic design of highly potent and selective small molecules that exhibit novel pharmacology. The company's Smart AllosteryTM technology platform utilizes AI-driven data mining of large and highly diverse data sets to identify pockets that matter on proteins, integrated with a tailored pharmacology toolkit and bespoke chemistry to rapidly deliver superior hotspot-targeted small molecules. The company has successfully exploited natural hotspots across multiple classes, including E3 ligases, kinases, and transcription factors. HotSpot has established a product pipeline of first-in-class small molecules for the treatment of cancer and autoimmune diseases, each enabled by precision and patient-targeted clinical design. To learn more, visit www.hotspotthera.com. SOURCE HotSpot Therapeutics

Predictive Intelligence
Strategic

ML-powered predictions for Hot Spot Therapeutics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.